Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy

According to results of a retrospective pharmacovigilance study, chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events. The analysis revealed disproportionate reporting of tachyarrhythmias, cardiomyopathy, pericardial and pleural disorders, and VTEs relative to background incidence across the FDA Adverse Event Reporting System database.